CNS Pharmaceuticals (CNSP) News Today $8.29 -0.19 (-2.24%) Closing price 03:58 PM EasternExtended Trading$8.26 -0.03 (-0.42%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period CNS Pharmaceuticals (NASDAQ:CNSP) Upgraded at Maxim GroupSeptember 15, 2025 | americanbankingnews.comCNS Pharmaceuticals upgraded to Buy from Hold at MaximSeptember 12, 2025 | msn.comCNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmapSeptember 12, 2025 | msn.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 16, 2025 | finanznachrichten.deCNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last yearAugust 16, 2025 | msn.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | finanznachrichten.deCNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comCNS Pharmaceuticals Participates in Virtual Investor CEO Connect ...July 11, 2025 | morningstar.comMCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deCNS Pharmaceuticals Acquires Orphan Drug Designation For TPI 287 And Prices $5M Public OfferingMay 15, 2025 | nasdaq.comCNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional InvestorMay 15, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287May 13, 2025 | finanznachrichten.deCNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer IndicationsMay 13, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesMay 13, 2025 | finanznachrichten.deCNS Pharmaceuticals files to sell 5.22M shares of common stock, warrantsApril 14, 2025 | markets.businessinsider.comCNS Pharmaceuticals sees cash runway into 1Q26April 2, 2025 | markets.businessinsider.comCNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last yearApril 2, 2025 | finance.yahoo.comCNS Pharmaceuticals announces primary analysis of berubicin in GBMMarch 26, 2025 | markets.businessinsider.comCNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBMMarch 26, 2025 | markets.businessinsider.comMaxim Group Downgrades CNS Pharmaceuticals (CNSP)March 26, 2025 | msn.comCNS Pharmaceuticals (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma TrialMarch 25, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma MultiformeMarch 25, 2025 | finanznachrichten.deCNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival EndpointMarch 25, 2025 | marketwatch.comCNS Pharmaceuticals shares tumble after clinical trial resultsMarch 25, 2025 | in.investing.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO ForumFebruary 27, 2025 | finanznachrichten.deCNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical ProgressFebruary 26, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ ListingFebruary 26, 2025 | finanznachrichten.deCNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ ListingFebruary 26, 2025 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor ConferenceFebruary 20, 2025 | theglobeandmail.comCNS Pharmaceuticals Inc trading halted, news pendingFebruary 20, 2025 | markets.businessinsider.comCNS Pharmaceuticals announces 1-for-50 reverse stock splitFebruary 19, 2025 | markets.businessinsider.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development SummitFebruary 18, 2025 | finanznachrichten.deCNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development SummitFebruary 18, 2025 | finance.yahoo.comCNS Pharmaceuticals to present at Glioblastoma Drug Development SummitFebruary 18, 2025 | markets.businessinsider.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor ConferenceFebruary 11, 2025 | theglobeandmail.comCNS Pharmaceuticals initiated with a Buy at Alliance Global PartnersJanuary 25, 2025 | markets.businessinsider.comAlliance Global Partners Initiates a Buy Rating on CNS Pharmaceuticals (CNSP)January 25, 2025 | markets.businessinsider.comCNSP stock touches 52-week low at $0.09 amid sharp declineJanuary 23, 2025 | msn.comCNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual MeetingNovember 20, 2024 | theglobeandmail.comCNS Pharmaceuticals sees cash runway through 2Q25November 16, 2024 | markets.businessinsider.comCNS Pharmaceuticals: Financial Results and Strategic MovesNovember 16, 2024 | markets.businessinsider.comCNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect EventNovember 5, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Secures $3 Million in Registered Direct OfferingOctober 25, 2024 | theglobeandmail.comWhy CNS Pharmaceuticals (CNSP) Stock Is Up 86%October 23, 2024 | benzinga.comCNS Pharma (NASDAQ:CNSP) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comCNS Pharma (NASDAQ:CNSP) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe ForumSeptember 23, 2024 | finanznachrichten.deBioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe ForumSeptember 23, 2024 | msn.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Regains Compliance with Nasdaq Equity RequirementSeptember 12, 2024 | finanznachrichten.deMaxim Group Upgrades CNS Pharmaceuticals (CNSP)September 11, 2024 | nasdaq.com Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSP Media Mentions By Week CNSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNSP News Sentiment▼0.000.71▲Average Medical News Sentiment CNSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNSP Articles This Week▼01▲CNSP Articles Average Week Get the Latest News and Ratings for CNSP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for CNS Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies EDSA News Today MTVA News Today NRSN News Today AIMD News Today CLRB News Today COCP News Today LPCN News Today IXHL News Today NBY News Today CMMB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNSP) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSP Stock Alerts